Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a
progestogen of the
retroprogesterone group which was developed by
Roche but was never marketed.[1][2][3] It shows greater
potency than
dydrogesterone in
bioassays.[4]
^Larsson-Cohn U, Johansson ED, Wide L, Gemzell C (September 1970). "Effects of daily administration of a retrosteroid on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens". The Journal of Obstetrics and Gynaecology of the British Commonwealth. 77 (9): 840–846.
doi:
10.1111/j.1471-0528.1970.tb04411.x.
PMID5458777.
S2CID6176278.
^Dixon R, Hudson S, Darragh A (1973). "Pharmacokinetics of the retro-steroid progestogen, 16α-ethylthio-9β,10α-pregna-4, 6-diene-3, 20-dione (Ro 6-3129), in man and the sheep". Contraception. 8 (1): 53–65.
doi:
10.1016/0010-7824(73)90159-5.
ISSN0010-7824.